Nkarta, Inc. NKTX
Regular-session close
After hours · Nov 16, 4:25 PM ET
- YTD
- -34.59%
- 1 year
- -35.29%
- Market cap
- 86.67M
- EPS (ttm)
- -1.77
- Shares out
- 70.57M
- Forward P/E
- -1.42
- YTD return
- -34.59%
- 1-year return
- -35.29%
- 50-day average
- 3.03
- 200-day average
- 5.86
- Volume
- 969.28K
- Avg volume
- 981.78K
- Open
- 1.20
- Previous close
- 1.19
- Day's range
- 1.20 – 1.28
- 52-week range
- 1.19 – 3.67
- Beta
- 0.87
- Price target
- 15.83 (+1208.5%)
Key statistics
- Enterprise value
- -30.36M
- Price / book
- 0.41
- Free cash flow
- -69.58M
- Total cash
- 283.06M
- Total debt
- 85.45M
- Return on equity
- -30.40%
- Short % of float
- 12.49%
Fundamental scorecard
4 of 25 checks passed on NKTX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.37 | -0.39 | -0.02 | -5.41% |
| Aug 13, 2024 | Jun 1, 2024 | -0.49 | -0.34 | +0.15 | +30.61% |
| Aug 13, 2024 | Jun 1, 2024 | -0.49 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.56 | -0.58 | -0.02 | -3.57% |
| May 9, 2024 | Mar 1, 2024 | -0.56 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | Mizuho | main | Outperform | Outperform |
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 8, 2024 | Needham | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Needham | reit | Buy | Buy |
| Aug 14, 2024 | Raymond James | up | Outperform | Strong Buy |
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nkartatx.com
News
Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications Nkarta Announces Integrated Safety Results From 40 Patients Treated With NKX019, Allogeneic, Off-The-Shelf, CD19-Directed CAR NK Cell Therapy Candidate In Ongoing Ntrust Clinical Trial Program
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript Nkarta Reports Initial Clinical Data For NKX019 Demonstrating Early Efficacy And Favorable Tolerability In Autoimmune Disease Trial
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
12 Health Care Stocks Moving In Friday's After-Market Session Nkarta To Host Webcast On November 9 To Review Initial Clinical Data From Ntrust Program Evaluating NKX019 In Myositis And Systemic Sclerosis Being Presented At ACR Convergence 2026
Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate
HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12
Your note
Sign in to keep a note on NKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANDENBERGER RALPH ERIK | Chief Technology Officer | Sale | Jun 17, 2024 | 79,743 |
| GEORGE SIMEON J. | Director | Purchase | Mar 26, 2024 | 0 |
| HAGER ALICIA J | Officer | Sale | Jul 15, 2024 | 103,819 |
| HASTINGS PAUL J | Chief Executive Officer | Sale | Jun 17, 2024 | 240,737 |
| LEVIN ALYSSA | Chief Financial Officer | Stock Award(Grant) | Jan 3, 2024 | 56,000 |
| MAHMOOD NADIR AHMEDUDDIN | Chief Financial Officer | Sale | Jun 19, 2023 | 85,776 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 15.31% | 10,805,129 | 27.01M | Sep 29, 2024 |
| Commodore Capital Lp | 6.61% | 4,662,073 | 11.66M | Sep 29, 2024 |
| Blackrock Inc. | 5.98% | 4,222,380 | 10.56M | Sep 29, 2024 |
| Boxer Capital, LLC | 5.71% | 4,029,606 | 10.07M | Sep 29, 2024 |
| Samsara BioCapital, LLC | 5.34% | 3,768,035 | 9.42M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 5.10% | 3,600,000 | 9.00M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.58% | 1,818,558 | 4.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.95% | 1,373,111 | 3.43M | Oct 30, 2024 |
| Wasatch Ultra Growth Fund | 1.45% | 1,024,570 | 2.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.00% | 704,875 | 1.76M | Sep 29, 2024 |
| Wasatch Microcap Fund | 0.95% | 668,362 | 1.67M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.77% | 542,221 | 1.36M | Aug 30, 2024 |
